Selected Publications

Esterling L, Wijayatunge R, Brown K, Morris B, Hughes E, Pruss D, Manley S, Bowles KR, Ross TS. Impact of a Cancer gene variant reclassification program over a 20-year period. JCO Precision Oncology, in press.

Sorelle JA, Gemmell AP and Ross TS.Different Interpretations of the Same Genetic Data. Annals of Internal Medicine, in press.

Ross TS, Pirzadeh-Miller SM, Lahiri S and Gemmell AP. Screening families of North Texans to identify individuals with a risk for cancer due to Lynch Syndrome. Texas Medicine 2019 Dec 1;115(12):e1

Sifuentes-Dominguez LF, Li H, Llano E, Liu Z, Singla A, Patel AS, Kathania M, Khoury A, Norris N, Rios JJ, Starokadomskyy P, Park JY, Gopal P, Liu Q, Tan S, Chan L, Ross TS, Harrison S, Venuprasad K, Baker LA, Jia D, Burstein E. SGN deficiency leads to colitis susceptibility. Elife 2019;8:e49910 Oct30

Gemmell AP, Mauer CB, Reys BD, Pirzadeh-Miller S and Ross TS. Family Still Matters: Counseling patients with complex family histories of colon and endometrial cancers. Molecular Genetics & Genomic Medicine 2019 Jul 26:e886.

Holmstrom SR, Wijayatunge R, McCrum K, Mgbemena VE and Ross TS. Functional Interaction of BRCA1 and CREBBP in Murine Hematopoiesis. iScience 2019;19: 809-820.

Wijayatunge R, Holmstrom SR, Foley SB, Mgbemena VE, Bhargava V, Perez GL, McCrum K, Ross T. Deficiency of the endocytic protein Hip1 leads to decreased Gdpd3 expression, low phospholcholine, and kypholordosis. Molecular and Cellular Biology 2018: 38(23).

Mersch J, Brown N, Pirzadeh-Miller S, Mundt E, Cox HC, Brown K, Aston M, Esterling L, Manley S, Ross T. Prevalence of variant reclassification following hereditary cancer genetic testing. JAMA 2018 Sep25; 320(12)1266-1274.

Mgbemena VE, Singer RA, Wijayatunge R, Laxson T, Morrison SJ, Ross TS. Distinct Brca1 mutations differentially reduce hematopoietic stem cell function. Cell Reports 2017 Jan24; 18(4):947-960,

Pirzadeh-Miller S, Robinson LS, ReadP, Ross TS. Genetic counseling assistants: An integral piece of the evolving genetic counseling service delivery model. Journal of Genetic Counseling 2016 Epub ahead of print.

Robinson LS, Hendrix A, Xie XJ, Yan J, Pirzadeh-Miller S, Pritzlaff M, Read P, Pass S, Euhus D and Ross TS. Prediction of cancer prevention: From mammogram screening to identification of BRCA1/2 mutation carriers in underserved populations. EBioMedicine 2(2015) 1827-1833 online.

Foley SB, Rios JJ, Mgbemena VE, Robinson LS, Hampel HL, Toland AE, Durham L, and Ross TS. Use of whole genome sequencing for diagnosis and discovery in the cancer genetics clinic. EBioMedicine 2015; 2(1) 74-81.

Ross TS. Democratization of genetic data: connecting government approval of clinical tests with data sharing. Cold Spring Harbor Molecular Case Studies 2015; 1: a000414.

Ross TS and Mgbemena VE. Re-evaluating the role of BCR/ABL in chronic myelogenous leukemia. Molecular & Cellular Oncology 1(3) 2014 e963450.

Yorczyk A, Robinson LS and Ross TS. Use of panel tests in place of single gene tests in the cancer genetics clinic. Clinical Genetics 2015:88:278-282.

Messa M , Ruben Fernandez-Busnadiego R, Sun EW, Chen Hong, Czapla H, Wrasman K, Wu Y, Ko G, Ross TS, Wendland B and De Camilli P. Epsin deficiency impairs endocytosis by stalling the actin-dependent invagination of endocytic clathrin coated pits. Elife 2014 Aug 13: e03311.

Pritzlaff M, Yorczyk A, Robinson LS, Pirzadeh-Miller S, Lin T, Euhus D, and Ross TS. An internal performance assessment of CancerGene Connect: An electronic tool to streamline, measure and improve the entire genetic counseling process. Journal of Genetic Counseling 23(6): 1034-1044, 2014.

Phillips ST, Hildenbrand ZL, Oravecz-Wilson KI, Foley SB, Mgbemena VE and Ross TS. Towards a therapeutic reduction of imatinib refractory myeloproliferative neoplasm-initiating cells. Oncogene 2014 Nov 13;33(46):5379-90; doi: 10.1038/onc.2013.484. Epub 2013 Nov 18.

Foley SB*, Hildenbrand ZL*, Soyombo AA, Magee JA, Wu Y, Oravecz-Wilson KI and Ross TS. Expression of BCR/ABL p210 from a knockin allele enhances bone marrow engraftment without inducing neoplasia. Cell Reports 5(1):51-60, 2013.

Soyombo AA*, Wu Y*, Kolski L, Rios JJ, Rakheda D, Chen A, Kehler J, Hampel H, Coughran A and Ross TS. Analysis of induced pluripotent stem cells from a BRCA1 mutant family.Stem Cell Reports 1(4): 336-349, 2013.

Ames HM*, Wang AA*, Coughran A, Evaul K, Huang S, Graves CW, Soyombo A and Ross TS. Huntingtin interacting protein 1 phosphorylation by receptor kinases. Molecular and Cellular Biology 33(18): 3580-3593, 2013.

Ames HM, Bichakjian CK, Liu GY, Oravecz-Wilson KI, Fullen DR, Verhaegen M, Johnson TM, Dlugosz, AA and Ross TS. Huntingtin interacting protein 1: a merkel cell carcinoma marker that Interacts with c-Kit. Journal of Investigative Dermatology 131(10):2113-20, 2011.

Oravecz-Wilson KI*, Philips ST*, Yilmaz OH, Li L, Crawford BD, Gauvin AM, Lucas PC, Sitwala K, Downing JR, Morrison SJ and Ross TS. Persistence of leukemia-initiating cells in a conditional knockin model of an imatinib-responsive myeloproliferative disorder. Cancer Cell 16(2):137-48, 2009.

Graves CW*, Philips ST*, Bradley SV, Oravecz-Wilson KI, Li L, Gauvin A and Ross TS. Use of a cryptic slice site for the expression of huntingtin interacting protein 1 in select normal and neoplastic tissues. Cancer Research 68(4):1064-73, 2008.

Bradley SV, Smith MR, Li L, Hyun TS, Lucas PC, Joshi I, Jin F, Antonuk D and Ross TS. Aberrant huntingtin interacting protein 1 in lymphoid malignancies. Cancer Research 67(18):8923-31, 2007.

Bradley SV*, Hyun TS*, Oravecz-Wilson KI, Li L, Waldorff E, Ermilov A, Goldstein S, Zhang CX, Drubin DG, Varela K, Parlow A, Dlugosz AA and Ross TS. Degenerative phenotypes caused by the combined deficiency of murine HIP1 and HIP1r are rescued by human HIP1. Human Molecular Genetics 16(11):1279-92, 2007.

Bradley SV, Holland EC, Liu GY, Thomas D, Hyun TS and Ross TS. Huntingtin interacting protein 1 Is a novel brain tumor marker that associates with epidermal growth factor receptor. Cancer Research 67(8):3609-15, 2007.

Bradley SV, Oravecz-Wilson KI, Gougeard G, Mizukami I, Li L, Munaco AJ, Sreekumar A, Chinnaiyan AM, Corradetti MN, Sanda MG and Ross TS. Serum antibodies to huntingtin interacting protein-1: a new blood test for prostate cancer. Cancer Research 65(10):4126-4133, 2005.

Hyun TS, Oravecz-Wilson KI, Li L, Munaco AJ, Provot MM, Mizukami IF and Ross TS. Hip1-related mutant mice grow and develop normally but have accelerated spinal abnormalities and dwarfism in the absence of HIP1. Molecular and Cellular Biology 24(10):4329-40, 2004.

Hyun TS and Ross TS. HIP1: Trafficking roles and regulation of tumorigenesis. Trends in Molecular Medicine 10(4):194-9, 2004.

Oravecz-Wilson KI , Kiel MJ, Rao DS, Saint-Dic D, Li L, Kumar PD, Provot MM, Bradley SV, Hankenson KD, Reddy VN, Lieberman AP, Morrison SJ, and Ross TS. Huntingtin interacting protein 1 mutations lead to abnormal hematopoiesis, spinal defects and cataracts. Human Molecular Genetics 13(8):851-867, 2004.

Hyun TS, Rao DS, Saint-Dic D, Michael E, Kumar PD, Bradley SV, Mizukami IF, Oravecz- Wilson KI, and Ross TS. HIP1 and HIP1r stabilize receptor tyrosine kinases and bind 3-phoshoinositides via epsin N-terminal homology domains. Journal of Biological Chemistry 279(14):14294-306, 2004.

Rao DS*, Bradley SV*, Kumar PD, Hyun TS, Saint-dic D, Oravecz-Wilson KI, Kleer CG and Ross TS. Altered receptor trafficking in huntingtin interacting protein 1-transformed cells. Cancer Cell 3:471-482, 2003.

Rao D S, Hyun T S, Mizukami I, Rubin M, Lucas P and Ross TS. Huntingtin-interacting protein 1 is overexpressed in cancer cells and its ENTH domain is critical for cellular survival. Journal of Clinical Investigation 110(3):351-360, 2002.

Mishra SK, Agostinelli NR, Brett TJ, Mizukami I, Ross TS and Traub LM. Clathrin and AP-2 binding sites in HIP1 uncover a general assembly role for endocytic accessory proteins. Journal of Biological Chemistry 276:46320-326, 2001.

Rao D., Chang JC, Kumar P, Mizukami I, Smithson GM, Bradley SV, Parlow AF and Ross TS. Huntingtin interacting protein 1 is a clathrin coat binding protein required for differentiation of late spermatogenic progenitors. Molecular and Cellular Biology 21:7796-7806, 2001.

Saint-Dic J, Chang SC, Taylor GS, Provot MM and Ross TS. Regulation of the SH2-containing inositol 5-phoshatase SHIP1 in HIP1/PDGFbetaR transformed cells. Journal of Biological Chemistry 276:21192-198, 2001.

Ross TS, Gilliland DG. Transforming properties of the huntingtin interacting protein 1/ platelet-derived growth factor β receptor fusion proteinJournal of Biological Chemistry 274:22328-22336, 1999.

Ross TS, Bernard OA, Berger R, Gilliland DG. Fusion of huntingtin interacting protein 1 to PDGFβR in chronic myelomonocytic leukemia with t(5;7)(q33;q11.2). Blood 91:4419-4426, 1998.